Revenue from Contract with Customer, Excluding Assessed Tax of HAEMONETICS CORP from 01 Jul 2017 to 27 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
HAEMONETICS CORP quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 01 Jul 2017 to 27 Dec 2025.
  • HAEMONETICS CORP Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 27 Dec 2025 was $338,967,000, a 2.7% decline year-over-year.
  • HAEMONETICS CORP Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 27 Dec 2025 was $1,318,275,000, a 4% decline year-over-year.
  • HAEMONETICS CORP annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $1,360,824,000, a 4% increase from 2023.
  • HAEMONETICS CORP annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $1,309,055,000, a 12% increase from 2022.
  • HAEMONETICS CORP annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $1,168,660,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

HAEMONETICS CORP Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,318,275,000 $338,967,000 -$9,575,000 -2.7% 28 Sep 2025 27 Dec 2025 10-Q 05 Feb 2026 2026 Q3
Q3 2025 $1,327,850,000 $327,315,000 -$18,196,000 -5.3% 29 Jun 2025 27 Sep 2025 10-Q 06 Nov 2025 2026 Q2
Q2 2025 $1,346,046,000 $321,394,000 -$14,778,000 -4.4% 30 Mar 2025 28 Jun 2025 10-Q 07 Aug 2025 2026 Q1
Q1 2025 $1,360,824,000 $330,599,000 -$12,691,000 -3.7% 29 Dec 2024 29 Mar 2025 10-K 21 May 2025 2025 FY
Q4 2024 $1,373,515,000 $348,542,000 +$12,292,000 +3.7% 29 Sep 2024 28 Dec 2024 10-Q 05 Feb 2026 2026 Q3
Q3 2024 $1,361,223,000 $345,511,000 +$27,328,000 +8.6% 30 Jun 2024 28 Sep 2024 10-Q 06 Nov 2025 2026 Q2
Q2 2024 $1,333,895,000 $336,172,000 +$24,840,000 +8% 31 Mar 2024 29 Jun 2024 10-Q 07 Aug 2025 2026 Q1
Q1 2024 $1,309,055,000 $343,290,000 +$38,874,000 +13% 31 Dec 2023 30 Mar 2024 10-K 21 May 2025 2025 FY
Q4 2023 $1,270,181,000 $336,250,000 +$30,949,000 +10% 01 Oct 2023 30 Dec 2023 10-Q 06 Feb 2025 2025 Q3
Q3 2023 $1,239,232,000 $318,183,000 +$20,698,000 +7% 02 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2025 Q2
Q2 2023 $1,218,534,000 $311,332,000 +$49,874,000 +19% 02 Apr 2023 01 Jul 2023 10-Q 08 Aug 2024 2025 Q1
Q1 2023 $1,168,660,000 $304,416,000 +$39,414,000 +15% 01 Jan 2023 01 Apr 2023 10-K 21 May 2025 2025 FY
Q4 2022 $1,129,246,000 $305,301,000 +$45,532,000 +18% 02 Oct 2022 31 Dec 2022 10-Q 08 Feb 2024 2024 Q3
Q3 2022 $1,083,714,000 $297,485,000 +$57,588,000 +24% 03 Jul 2022 01 Oct 2022 10-Q 02 Nov 2023 2024 Q2
Q2 2022 $1,026,126,000 $261,458,000 +$32,930,000 +14% 03 Apr 2022 02 Jul 2022 10-Q 08 Aug 2023 2024 Q1
Q1 2022 $993,196,000 $265,002,000 02 Jan 2022 02 Apr 2022 10-K 20 May 2024 2024 FY
Q4 2021 $259,769,000 +$19,398,000 +8.1% 03 Oct 2021 01 Jan 2022 10-Q 07 Feb 2023 2023 Q3
Q3 2021 $239,897,000 +$30,411,000 +15% 04 Jul 2021 02 Oct 2021 10-Q 08 Nov 2022 2023 Q2
Q2 2021 $228,528,000 +$32,951,000 +17% 04 Apr 2021 03 Jul 2021 10-Q 10 Aug 2022 2023 Q1
Q4 2020 $240,371,000 -$18,599,000 -7.2% 27 Sep 2020 26 Dec 2020 10-Q 08 Feb 2022 2022 Q3
Q3 2020 $209,486,000 -$43,080,000 -17% 28 Jun 2020 26 Sep 2020 10-Q 09 Nov 2021 2022 Q2
Q2 2020 $195,577,000 -$42,874,000 -18% 29 Mar 2020 27 Jun 2020 10-Q 11 Aug 2021 2022 Q1
Q4 2019 $258,970,000 +$11,614,000 +4.7% 29 Sep 2019 28 Dec 2019 10-Q 02 Feb 2021 2021 Q3
Q3 2019 $252,566,000 +$10,985,000 +4.5% 30 Jun 2019 28 Sep 2019 10-Q 04 Nov 2020 2021 Q2
Q2 2019 $238,451,000 +$9,104,000 +4% 31 Mar 2019 29 Jun 2019 10-Q 04 Aug 2020 2021 Q1
Q4 2018 $247,356,000 +$13,313,000 +5.7% 30 Sep 2018 29 Dec 2018 10-Q 04 Feb 2020 2020 Q3
Q3 2018 $241,581,000 +$16,204,000 +7.2% 01 Jul 2018 29 Sep 2018 10-Q 01 Nov 2019 2020 Q2
Q2 2018 $229,347,000 +$18,396,000 +8.7% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2020 Q1
Q4 2017 $234,043,000 01 Oct 2017 30 Dec 2017 10-Q 05 Feb 2019 2019 Q3
Q3 2017 $225,377,000 02 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2019 Q2
Q2 2017 $210,951,000 02 Apr 2017 01 Jul 2017 10-Q 07 Aug 2018 2019 Q1

HAEMONETICS CORP Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,360,824,000 +$51,769,000 +4% 31 Mar 2024 29 Mar 2025 10-K 21 May 2025 2025 FY
2023 $1,309,055,000 +$140,395,000 +12% 02 Apr 2023 30 Mar 2024 10-K 21 May 2025 2025 FY
2022 $1,168,660,000 +$175,464,000 +18% 03 Apr 2022 01 Apr 2023 10-K 21 May 2025 2025 FY
2021 $993,196,000 04 Apr 2021 02 Apr 2022 10-K 20 May 2024 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.